Lung Cancer Trial, Recruiting (NCT07207278)

Lung Cancer Trial, Recruiting NCT07207278 Sponsor: First People's Hospital of Hangzhou Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07207278 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a specific type of lung cancer called lung signet ring cell carcinoma (LSRCC), confirmed through a tissue sample, and have not received any treatment for it yet.
Suitable tumor tissue samples (preserved in a specific way) and nearby non-tumor tissue are available for testing.
Your doctor expects you to live for at least 12 weeks or more.
You (or your legal guardian) are willing and able to sign a consent form agreeing to take part.
Your complete pathology (lab test) results and scan/imaging records are available.

Who may not be able to join:

You have previously received any cancer treatment given through your whole body (such as chemotherapy or immunotherapy).
Your signet ring cell carcinoma started somewhere else in your body and has spread to the lungs, rather than starting in the lungs.
You currently have another type of cancer at the same time.
Your lab results, scan records, or follow-up information are incomplete or unreliable.
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-0571-56007664

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07207278

Sponsor: First People's Hospital of Hangzhou

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +86-0571-56007664

More information: https://clinicaltrials.gov/study/NCT07207278

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a specific type of lung cancer called lung signet ring cell carcinoma (LSRCC), confirmed through a tissue sample, and have not received any treatment for it yet.
Suitable tumor tissue samples (preserved in a specific way) and nearby non-tumor tissue are available for testing.
Your doctor expects you to live for at least 12 weeks or more.
You (or your legal guardian) are willing and able to sign a consent form agreeing to take part.
Your complete pathology (lab test) results and scan/imaging records are available.

Who may not be able to join:

You have previously received any cancer treatment given through your whole body (such as chemotherapy or immunotherapy).
Your signet ring cell carcinoma started somewhere else in your body and has spread to the lungs, rather than starting in the lungs.
You currently have another type of cancer at the same time.
Your lab results, scan records, or follow-up information are incomplete or unreliable.
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

First People's Hospital of Hangzhou

Registry

ClinicalTrials.gov

Start date

1 September 2025

Est. completion

31 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Week 8 Objective Response Rate (ORR) by RECIST v1.1 in ALK Fusion-Positive LSRCC Patients with Hybrid TIME Subtype

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov